About oxford biomedica plc - OXBDF
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.
OXBDF At a Glance
Oxford Biomedica Plc
Windrush Court
Oxford, Oxfordshire OX4 6LT
| Phone | 44-1865-783-000 | Revenue | 222.38M | |
| Industry | Biotechnology | Net Income | -39,705,397.78 | |
| Sector | Health Technology | 2025 Sales Growth | 35.122% | |
| Fiscal Year-end | 12 / 2026 | Employees | 861 | |
| View SEC Filings |
OXBDF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.177 |
| Price to Book Ratio | 7.157 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -55.27 |
| Enterprise Value to Sales | 4.487 |
| Total Debt to Enterprise Value | 0.20 |
OXBDF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 2.537 |
| Total Asset Turnover | 0.611 |
OXBDF Liquidity
| Current Ratio | 2.204 |
| Quick Ratio | 1.999 |
| Cash Ratio | 1.15 |
OXBDF Profitability
| Gross Margin | 39.101 |
| Operating Margin | -19.878 |
| Pretax Margin | -18.926 |
| Net Margin | -17.855 |
| Return on Assets | -10.905 |
| Return on Equity | -40.868 |
| Return on Total Capital | -12.327 |
| Return on Invested Capital | -15.387 |
OXBDF Capital Structure
| Total Debt to Total Equity | 162.161 |
| Total Debt to Total Capital | 61.856 |
| Total Debt to Total Assets | 45.477 |
| Long-Term Debt to Equity | 155.531 |
| Long-Term Debt to Total Capital | 59.326 |